ClinicalTrials.gg
CompletedNCT07636096Updated Jun 9, 2026

Breast Phyllodes Tumors: Based on 20-year Real-world Data From China

An observational study in Phyllodes Breast Tumor and Prognosis, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,500
Sex
All
01

Study summary

Phyllodes tumor (PT) is a rare type of breast tumor made up of both connective tissue (stroma) and gland tissue (epithelium). It accounts for less than 1% of all breast tumors. The main symptom is a fast-growing, painless lump.

Based on its appearance under a microscope, the World Health Organization (WHO) classifies PT into three grades: benign (non-cancerous), borderline (intermediate), and malignant (cancerous). The chance of the tumor coming back after treatment (recurrence) is about 7%, 17%, and 25% for each grade, respectively. The average age when patients are diagnosed is between 36 and 55 years, and the typical tumor size ranges from about 4 to 11 cm. Malignant PT can spread to other parts of the body (metastasis) in up to 6% to 62% of cases, most often to the lungs or bones through the bloodstream.

Because PT is rare, large studies on its causes, diagnosis, treatment, and long-term outlook are very limited. PT can grow very quickly. Delaying diagnosis and treatment may allow the tumor to become so large that surgery is no longer an option. Standard imaging tests (ultrasound, mammogram, MRI) have limited ability to tell the difference between benign and malignant PT. Also, since these tumors are often large and vary from one area to another, a small needle biopsy may not show the whole picture. An accurate grade is usually only possible after the whole tumor is removed and examined by a pathologist.

PT does not respond well to radiation or chemotherapy. Therefore, the main treatment is complete surgical removal with clear margins. The role of newer therapies such as targeted therapy or immunotherapy is still being studied. Although the WHO grade gives some idea of how the patient might do, some benign PT can come back many times or even turn malignant, while some malignant PT stay stable for a long time. The current grading system does not fully explain why individual outcomes differ.

In recent years, most prediction models for PT have been built using Western patient data (for example, from the SEER database). These models have not been tested in Asian populations. They are usually based on small, single-center studies with dozens to a few hundred patients, and many have only been checked inside the same database without outside (external) validation. Most studies focus on symptoms, imaging findings, how to tell benign from malignant PT, or comparing different types of surgery. Few have looked closely at patterns of recurrence and metastasis, or risk factors for rare events like multiple recurrences, distant spread, or death.

To fill these gaps, we plan to conduct a large, multi-center, retrospective (looking back at past medical records) study across 8 top hospitals in China. We will use real-world data from about 3,500 patients with breast PT diagnosed between 2001 and 2023. The main goals are to describe the clinical and pathological features, treatment patterns, and long-term outcomes of Chinese PT patients. The main outcomes we will measure are local recurrence, distant metastasis, and overall survival. Secondary outcomes include disease characteristics and current treatment practices. This study aims to provide evidence from the Chinese population to help guide personalized treatment and future updates to clinical guidelines.

02

Conditions studied

  • Phyllodes Breast Tumor
  • Prognosis
03

In context

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study includes patients who underwent surgical resection for breast phyllodes tumor (PT) at one of eight tertiary hospitals in China between January 1, 2001, and December 31, 2023. All patients with a postoperative paraffin-embedded pathology diagnosis of benign, borderline, or malignant PT according to WHO criteria are included. Exclusion criteria are: (1) PT with uncertain behavior or unclassified grade; (2) history of prior malignancy (excluding breast cancer) with less than 5 years disease-free survival, or concurrent diseases that may affect endpoint assessment; (3) loss to follow-up or missing critical data (pathological grade, surgical procedure, or follow-outcome). A total of approximately 3,500 eligible patients from eight participating centers will be enrolled. All patients are of Chinese ethnicity.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Breast phyllodes tumors (benign, borderline, or malignant) based on postoperative paraffin pathology according to WHO criteria
  • Underwent surgical treatment
  • Complete or substantially complete clinical records, pathology reports, and follow-up data

Exclusion criteria

Exclusion Criteria:

  • Phyllodes without histological grading
  • Hstory of other concomitant diseases that may affect the assessment of the study endpoint events
  • Patients lost to follow-up or with missing key data
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,500 participants (actual)
Patient registry
No

Groups and cohorts

  • Benign Phyllodes Tumor
  • Borderline Phyllodes Tumor
  • Malignant Phyllodes Tumor
06

What researchers measure

Primary outcomes

  1. Local Recurrence, LR

    Recurrence was defined as pathologically confirmed reoccurrence of phyllodes tumor in the ipsilateral breast, chest wall, or axillary lymph nodes after initial surgery, based on postoperative follow-up records (including outpatient visits, hospitalizations, and imaging findings) and pathology reports

    Time frame: 3 year

  2. Overall Survival, OS

    Overall survival was defined as the time interval from the date of initial surgery to the date of death from any cause, measured in months. Patients who remained alive were censored at the date of their last follow-up

    Time frame: 3 year

  3. Distant Metastasis, DM

    Extramammary organ metastasis (including but not limited to the lungs, liver, bones, and brain) confirmed by imaging studies (CT, PET-CT, bone scan, etc.) and/or pathological examination

    Time frame: 3 year

07

Study locations

1 site
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510120, China
08

References and documents

Publications

  • Varghese S, Seldon Y, Raperport C, Rinne N, Patel K, Zaid RZ. Isolated fallopian tube torsion: A systematic review of case reports. Eur J Obstet Gynecol Reprod Biol. 2024 May;296:140-147. doi: 10.1016/j.ejogrb.2024.02.050. Epub 2024 Feb 29. PubMed 38432020 ↗
  • Takeda I, Yamada A, Onodera H. Artificial Intelligence-Assisted motion capture for medical applications: a comparative study between markerless and passive marker motion capture. Comput Methods Biomech Biomed Engin. 2021 Jun;24(8):864-873. doi: 10.1080/10255842.2020.1856372. Epub 2020 Dec 8. PubMed 33290107 ↗
  • Jansaka N, Suprasert P. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center. Asian Pac J Cancer Prev. 2014;15(24):10837-40. doi: 10.7314/apjcp.2014.15.24.10837. PubMed 25605186 ↗
  • Ostrauskas R, Zalinkevicius R, Jurgeviciene N, Radzeviciene L, Lasaite L. The incidence of type 1 diabetes mellitus among 15-34 years aged Lithuanian population: 18-year incidence study based on prospective databases. BMC Public Health. 2011 Oct 19;11:813. doi: 10.1186/1471-2458-11-813. PubMed 22011463 ↗
  • Gupta PJ. Randomized controlled study: radiofrequency coagulation and plication versus ligation and excision technique for rectal mucosal prolapse. Am J Surg. 2006 Aug;192(2):155-60. doi: 10.1016/j.amjsurg.2006.03.012. PubMed 16860622 ↗
  • Maeshima A, Zhang YQ, Furukawa M, Naruse T, Kojima I. Hepatocyte growth factor induces branching tubulogenesis in MDCK cells by modulating the activin-follistatin system. Kidney Int. 2000 Oct;58(4):1511-22. doi: 10.1046/j.1523-1755.2000.00313.x. PubMed 11012886 ↗
  • Zhang Y, Kleer CG. Phyllodes Tumor of the Breast: Histopathologic Features, Differential Diagnosis, and Molecular/Genetic Updates. Arch Pathol Lab Med. 2016 Jul;140(7):665-71. doi: 10.5858/arpa.2016-0042-RA. PubMed 27362571 ↗
  • Miller AR, Wijeratne S, McGrath SD, Schieffer KM, Miller KE, Lee K, Mathew M, LaHaye S, Fitch JR, Kelly BJ, White P, Mardis ER, Wilson RK, Cottrell CE, Magrini V. Pacific Biosciences Fusion and Long Isoform Pipeline for Cancer Transcriptome-Based Resolution of Isoform Complexity. J Mol Diagn. 2022 Dec;24(12):1292-1306. doi: 10.1016/j.jmoldx.2022.09.003. Epub 2022 Sep 30. PubMed 36191838 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in May 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 9, 2026
StartActual
May 1, 2026
Primary completionActual
May 1, 2026
CompletionActual
May 20, 2026
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07636096
Collaborators
Sun Yat-Sen University Cancer Center, The First Affiliated Hospital of Guangzhou Medical University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, Peking University Shenzhen Hospital, Foshan Women's and Children's Hospital
Responsible party
Yan Nie (principal investigator, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Jun 9, 2026
Start date
May 1, 2026
Primary completion
May 1, 2026
Completion
May 20, 2026
Last update
Jun 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion